



# BETA DRUGS LIMITED

**BDL/PKL/SEC/2023**  
**24<sup>th</sup> November, 2023**

To,  
The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block-G  
Bandra Kurla Complex  
Bandra East  
Mumbai 400051

**NSE Symbol: BETA**

Dear Sir/Madam

**Sub:-Beta Drugs Limited Earns Prestigious Spot on Forbes List of '200 Best Under a Billion'.**

Beta Drugs, is a leading oncology company, proudly announces its inclusion in the esteemed Forbes list of the '200 Best Under a Billion' companies. This recognition is a testament to the company's sustained growth, financial strength, and commitment to excellence in the pharmaceutical industry.



**CIN No.:** L24230HP2005PLC028969

**Admin. Office :** SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

**Registered Office & Works:** Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

**Website :-** [www.betadrugslimited.com](http://www.betadrugslimited.com)

**E-Mail :-** [info@betadrugslimited.com](mailto:info@betadrugslimited.com)



# BETA DRUGS LIMITED

Beta inclusion in this exclusive list is a reflection of its strategic vision, operational efficiency, and sustained positive impact on the healthcare sector. This prestigious accolade recognizes the company's impact on a global scale, showcasing the company's dedication to upholding the highest quality standards to improve lives worldwide.

Mr. Rahul Batra, Chairman and Managing Director of Beta Drugs Limited, expressed his gratitude for this prestigious acknowledgment stating, "Being recognized by Forbes is a tremendous honor and a validation of the hard work and dedication of the entire team. Our commitment to innovation, quality, and delivering value to our stakeholders has been integral to our success."

Forbes, a globally renowned business publication, annually curates the '200 Best Under a Billion' list to showcase companies that have demonstrated exceptional performance in terms of revenue growth, profitability, and overall business excellence.

The selection process involved evaluating over 20,000 publicly traded companies spanning the Asia-Pacific region. The chosen 200 enterprises share a common characteristic of maintaining annual sales under \$1 billion. Only two pharmaceutical companies from the Asia Pacific region have been featured in the 2023 list.

This recognition from Forbes serves as a noteworthy milestone in the company's journey, further solidifying its position as a key player in the pharmaceutical industry.

This is for your information and appropriate dissemination.

Thanking You

Your's faithfully  
For Beta Drugs Limited



Rajni Brar  
Company Secretary

**CIN No.:** L24230HP2005PLC028969

**Admin. Office :** SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

**Registered Office & Works:** Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

**Website :-** [www.betadrugslimited.com](http://www.betadrugslimited.com)

**E-Mail :-** [info@betadrugslimited.com](mailto:info@betadrugslimited.com)